Peer-Reviewed Publications - Shari Pilon-Thomas, Ph.D.

 

  1. Dukes CW, Rossetti RAM, Hensel JA, Snedal S, Cubitt CL, Schell MJ, Abrahamsen M, Isaacs-Soriano K, Kennedy K, Mangual LN, Whiting J, Martinez-Brockhus V, Islam JY, Rathwell J, Beatty M, Hall AM, Abate-Daga D, Giuliano AR, & Pilon-Thomas S. SARS-CoV-2 Antibody Response Duration and Neutralization Following Natural Infection [published online ahead of print]. J Clin Virol Plus. 2023;3(3). doi:10.1016/j.jcvp.2023.100158
  2. Hall MS, Mullinax JE, Cox CA, Hall AM, Beatty MS, Blauvelt J, Innamarato P, Nagle L, Branthoover H, Wiener D, Schachner B, Martinez AJ, Richards AD, Rich CJ, Colon Colon M, Schell MJ, Teer JK, Khushalani NI, Weber JS, Mule JJ, Sondak VK, Pilon-Thomas S, Sarnaik AA. Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Clin Cancer Res. 2022. Epub 20221010. doi: 10.1158/1078-0432.CCR-22-2103. PubMed PMID: 36215121
  3. Giuliano AR, Kuter BJ, Pilon-Thomas S, Whiting J, Mo Q, Leav B, Sirak B, Cubitt CL, Dukes C, Isaacs-Soriano K, Kennedy K, Ball S, Dong N, Jain A, Hwu P, & Lancet JE. Safety and Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients [published online ahead of print, 2023 Jun 28]. Cancer Commun (Lond). 2023;10.1002/cac2.12453. doi:10.1002/cac2.12453
  4. Gallen C, Dukes CW, Aldrich A, Macaisa L, Mo Q, Cubitt CL, Pilon-Thomas S, Giuliano AR, Czerniecki BJ, & Costa RLB. Long-Term CD4+ T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study. Vaccines. 2022;10(11):1931. doi:10.3390/vaccines10111931
  5. Giuliano AR, Lancet JE, Pilon-Thomas S, Dong N, Jain AG, Tan E, Ball S, Tworoger SS, Siegel EM, Whiting J, Mo Q, Cubitt CL, Dukes CW, Hensel JA, Keenan RJ, & Hwu P. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida. JAMA Oncol. 2022;8(5):748-754. doi:10.1001/jamaoncol.2022.0001
  6. Giuliano AR, Pilon-Thomas S, Schell MJ, Abrahamsen M, Islam JY, Isaacs-Soriano K, Kennedy K, Dukes CW, Whiting J, Rathwell J, Hensel JA, Mangual LN, Schonbrunn E, Bikowitz M, Grassie D, & Yang Y. SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020-March 2021. Emerg Infect Dis. 2022;28(3):556-563. doi:10.3201/eid2803.211495
  7. Aydin AM, Hall M, Bunch BL, Branthoover H, Sannasardo Z, Mackay A, Beatty M, Sarnaik AA, Mullinax JE, Spiess PE, Pilon-Thomas S. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. Int Immunopharmacol. 2021 Feb 23;94:107481. doi: 10.1016/j.intimp.2021. PMID: 10748133636562
  8. Innamarato P, Pilon-Thomas S. Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapy. Cell Immunol. 2021 Mar;361:104277. doi: 10.1016/j.cellimm.2020.104277. Epub 2020 Dec 26. PMID: 33476931
  9. Mullinax JE, Hall M, Beatty M, Weber AM, Sannasardo Z, Svrdlin T, Richards A, Gonzalez RJ, Cox CA, Kelley L, Mulé JJ, Sarnaik AA, Pilon-Thomas S. Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function. J Immunother. 2021 Jan 11. doi: 10.1097/CJI.0000000000000355. Online ahead of print. PMID: 33443972
  10. Wu H, Estrella V, Beatty M, Abrahams D, El-Kenawi A, Russell S, Ibrahim-Hashim A, Longo DL, Reshetnyak YK, Moshnikova A, Andreev OA, Luddy K, Damaghi M, Kodumudi K, Pillai SR, Enriquez-Navas P, Pilon-Thomas S, Swietach P, Gillies RJ. T-cells produce acidic niches in lymph nodes to suppress their own effector functions. Nat Commun. 2020 Aug 17;11(1):4113. doi: 10.1038/s41467-020-17756-7. PMID: 32807791
  11. Mohamed E, Sierra RA, Trillo-Tinoco J, Cao Y, Innamarato P, Payne KK, de Mingo Pulido A, Mandula J, Zhang S, Thevenot P, Biswas S, Abdalla SK, Costich TL, Hänggi K, Anadon CM, Flores ER, Haura EB, Mehrotra S, Pilon-Thomas S, Ruffell B, Munn DH, Cubillos-Ruiz JR, Conejo-Garcia JR, Rodriguez PC. The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. Immunity. 2020 Apr 14;52(4):668-682.e7. doi: 10.1016/j.immuni.2020.03.004. PMID: 32294407
  12. Innamarato P, Asby S, Morse J, Mackay A, Hall M, Kidd S, Nagle L, Sarnaik AA, Pilon-Thomas S. Intratumoral Activation of 41BB Costimulatory Signals Enhances CD8 T Cell Expansion and Modulates Tumor-Infiltrating Myeloid Cells. J Immunol. 2020 Nov 15;205(10):2893-2904. doi: 10.4049/jimmunol.2000759. Epub 2020 Oct 5. PMID: 33020146
  13. Innamarato P, Kodumudi K, Asby S, Schachner B, Hall M, Mackay A, Wiener D, Beatty M, Nagle L, Creelan BC, Sarnaik AA, Pilon-Thomas S. Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy. Mol Ther. 2020 Oct 7;28(10):2252-2270. doi: 10.1016/j.ymthe.2020.06.025. Epub 2020 Jun 24. PMID: 32615068
  14. Bunch BL, Morse J, Asby S, Blauvelt J, Aydin AM, Innamarato P, Hajiran A, Beatty M, Poch M, Pilon-Thomas S. Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo. J Immunother Cancer. 2020 Dec;8(2):e001673. doi: 10.1136/jitc-2020-001673. PMID: 33303579
  15. Hopewell EL, Cox C, Pilon-Thomas S, Kelley LL. Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process. Cytotherapy. 2019 Mar;21(3):307-314. doi: 10.1016/j.jcyt.2018.11.004. Epub 2018 Dec 1. PMID: 30509772
  16. Falahat R, Perez-Villarroel P, Mailloux AW, Zhu G, Pilon-Thomas S, Barber GN, Mulé JJ. STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity. Cancer Immunol Res. 2019 Nov;7(11):1837-1848. doi: 10.1158/2326-6066.CIR-19-0229. Epub 2019 Aug 28. PMID: 31462408
  17. El-Kenawi A, Gatenbee C, Robertson-Tessi M, Bravo R, Dhillon J, Balagurunathan Y, Berglund A, Vishvakarma N, Ibrahim-Hashim A, Choi J, Luddy K, Gatenby R, Pilon-Thomas S, Anderson A, Ruffell B, Gillies R. Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer. Br J Cancer. 2019 Oct;121(7):556-566. doi: 10.1038/s41416-019-0542-2. Epub 2019 Aug 16. PMID: 31417189
  18. Atay C, Kwak T, Lavilla-Alonso S, Donthireddy L, Richards AD, Moberg VE, Pilon-Thomas S, Schell MJ, Messina JL, Rebecca VW, Xiao M, Tan J, Zhang G, Weber JS, Herlyn M, Sarnaik AA, Gabrilovich DI. BRAF targeting sensitizes resistant melanoma to cytotoxic T cells. Clin Cancer Res. 2019 Feb 14. pii: clincanres.2725.2018. doi: 10.1158/1078-0432.CCR-18-2725. PMID: 30765391
  19. Hopewell EL, Cox C, Pilon-Thomas S, Kelley LL. Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process. Cytotherapy. 2018 Nov 30. pii: S1465-3249(18)30674-1. PMID: 30509772
  20. Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S. Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer.  Oncoimmunology. 2018 Jul 23;7(9):e1476816. PMCID: PMC6140546
  21. Liu H, Weber A, Morse J, Kodumudi K, Scott E, Mullinax J, Sarnaik AA, Pilon-Thomas S. T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model. PLoS One. 2018 Apr 25;13(4):e0196033. PMCID: PMC5918896
  22. Mullinax, JE, Hall, M., Prabhakaran, S., Weber, J, Khushalani, N., Eroglu, Z, Brohl, A., Markowitz,J., Royster, E., Richards, A., Stark, V.,  Zager, JS.,  Kelley, L., Cox,C., Sondak, VK., Mule', JJ., Pilon-Thomas, S.*, and  Sarnaik, AA.  Combination Ipilimumab and Adoptive Cell Therapy with Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma.  Frontiers in Oncology. 2018. Front Oncol. 2018 Mar 2;8:44. PMCID: PMC5840208. *corresponding author and shared senior authorship
  23. Hall, M., Liu, H., Malafa, M., Centeno, B., Pimiento, J., Hodel, P., Pilon-Thomas, S.*, Sarnaik, AA. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. J Immunother Cancer. 4:61.2016. PMCID: PMC5067894. *shared senior authorship
  24. Liu H, Innamarato PP, Kodumudi K, Weber A, Nemoto S, Robinson JL, Crago G, McCardle T, Royster E, Sarnaik AA, Pilon-Thomas S. Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1. Oncotarget. 2016. PMCID: PMC5122358
  25. Kodumudi KN, Siegel J, Weber AM, Scott E, Sarnaik AA, Pilon-Thomas S. Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy. PLoS One.11(4):e0153053. 2016. PMCID:PMC4822778
  26. Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K, Damaghi M, Wojtkowiak JW, Mulé JJ, Ibrahim-Hashim A, Gillies RJ. Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res. 76(6):1381-90, 2016. PMCID: PMC4829106
  27. Chacon, J., Sarnaik, A.A., Chen, J., Creasy, C., Kale, C., Robinson, J., Weber, J., Hwu, P., Pilon-Thomas, S.*, and Radvanyi, L. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy. Clinical Cancer Research, 21(3):611-21, 2015. PMCID: PMC4315752 *shared senior authorship
  28. Chacon, J.A., Pilon-Thomas, S., Sarnaik, A.A., Radvanyi, L.G. Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology. 2(9):e25581, 2013. PMID: 24319633; PMCID: PMC3850170.
  29. Toomey, P., Kodumudi, K., Weber, A., Kuhn, L., Moore, E., Sarnaik, A.A., Pilon-Thomas, S. Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS One. 8(7):e68561, 2013. PMCID: PMC3714270
  30. Ghansah, T., Vohra, N., Kinney, K., Weber, A., Kodumudi, K., Springett, G., Sarnaik, A.A., Pilon-Thomas, S. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma. Cancer Immunol Immunother., 62(6):1083-91, 2013. PMCID: PMC3666559
  31. Chacon, J.A., Wu, R.C., Sukhumalchandra, P., Molldrem, J.J., Sarnaik A, Pilon-Thomas, S., Weber, J., Hwu, P., Radvanyi, L. Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy. PLoS One, 8(4):e60031, 2013. Epub 2013 Apr 1. PMCID: PMC3613355
  32. Kodumudi, K., Weber, A., Sarnaik, A.A., Pilon-Thomas, S. Blockade of myeloid derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. Journal of Immunology 189(11): 5147-54, 2012. PMCID: PMC3505990
  33. Pilon-Thomas, S., Kuhn, L., Ellwanger, S., Janssen, W., Royster, E., Marzban, S., Kudchadkar, R., Zager, J., Gibney, G., Sondak, V.K., Weber, J., Mulé, J.J., Sarnaik, A.A. Brief Communication: Efficacy of Adoptive Cell Transfer of Tumor Infiltrating Lymphocytes after Lymphopenia Induction for Metastatic Melanoma. Journal of Immunotherapy 35:615-20, 2012. PMCID: PMC4467830
  34. Pilon-Thomas, S., Nelson, N., Vohra, N., Jerald, M., Pendleton, L., Szekeres,K, and Ghansah, T. Murine pancreatic adenocarcinoma dampens SHIP-1 expression and alters MDSC homeostasis and function.  PLoS One, 6:e27729, 2011.  PMCID: PMC3222660
  35. Pilon-Thomas, S.A., Mackay, A., Vohra, N., and Mulé, J.J. Blockade of Programmed Death Ligand-1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J. Immunol. 184:3442-3449, 2010.  PMCID: PMC2913584